Opaleye Management’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Opaleye Management’s Portfolio FOMX Stock Details FOMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-180,000	Closed	-$675K	–	59
2019 Q1	$675K	Buy	+180,000	New	+$674K	0.19%	50
2018 Q4	–	Sell	-91,000	Closed	-$521K	–	59
2018 Q3	$521K	Sell	91,000 -159,000	-64%	-$910K	0.13%	46
2018 Q2	$3.83M	Sell	250,000 -700,000	-74%	-$3.6M	0.99%	30
2018 Q1	$4.87M	Sell	950,000 -10,000	-1%	-$60.2K	1.39%	22
2017 Q4	$5.77M	Sell	960,000 -182,000	-16%	-$1.1M	1.85%	18
2017 Q3	$6.34M	Buy	1,142,000 +7,000	+0.6%	+$36.2K	2.24%	15
2017 Q2	$5.27M	Buy	1,135,000 +635,000	+127%	+$2.83M	2.2%	15
2017 Q1	$2.48M	Buy	500,000 +5,000	+1%	+$48.1K	1.23%	26
2016 Q4	$5.5M	Sell	495,000 -135,000	-21%	-$1.27M	3.24%	6
2016 Q3	$5.83M	Sell	630,000 -65,000	-9%	-$543K	3.05%	7
2016 Q2	$4.41M	Buy	695,000 +105,000	+18%	+$697K	2.95%	11
2016 Q1	$3.85M	Buy	590,000 +90,000	+18%	+$580K	2.4%	18
2015 Q4	$4.05M	Buy	500,000 +215,000	+75%	+$1.61M	1.7%	26
2015 Q3	$2.09M	Buy	285,000 +200,000	+235%	+$2.04M	1.03%	37
2015 Q2	$871K	Buy	+85,000	New	+$939K	0.35%	41

Other funds holding FOMX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Opaleye Management's FOMX Position: Q2 2019 in Review

Opaleye Management sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q2 2019, closing a stake of 180,000 shares — an estimated $675K sold.

Opaleye Management first reported a position in FOMX in Q2 2015 and held it in 15 quarters. The position peaked at $6.34M in Q3 2017. 58 funds tracked by Wall St. Rank hold FOMX as of Q2 2019.

Opaleye Management reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q2 2019 after selling out during the quarter.
Opaleye Management sold 180,000 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q2 2019, an estimated $675K.
Opaleye Management first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and held it in 15 quarters.
Opaleye Management's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $6.34M in Q3 2017.
58 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q2 2019.

Based on Opaleye Management's 13F filing for Q2 2019, filed 14 Aug 2019.